| Paris | |
| 626 | |
| The Company develops first in class drugs that focus on cancer immunotherapy through the manipulation of the innate immune system. | |
| The Company has three clinical-stage programs, including two checkpoint inhibitors in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the bodys own immune cells to recognize and kill cancer cells. Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Novo Nordisk A/S, Bristol-Myers Squibb and AstraZeneca. | |
| MERCIER Laure Helene | |
| www.innate-pharma.com | |
| IPH:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 52 fois.